Subtype: HR-Positive & HER2-negative
A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)
Phase III, Line of treatment: 1nd Line, Received at least 24 months of AI treatment as part of their adjuvant therapy and at least 12 months have elapsed since the patient’s last dose of adjuvant AI therapy without disease progression on treatment
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR JOHN LOW SENG HOOI
john.low@pantaidr.my
CONTACT
SC: Wei Ying 03-79492120 (Research Room)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Ho Gwo Fuang
fuang@ummc.edu.my
CONTACT
SC: Wei Ying 03-79492120 (Research Room)
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
Dr Vaishnavi Jeyasingam
vaishnavijeyasingam@yahoo.com
CONTACT
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Dr. Ngu Ming Ruey
rueyngu@gmail.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
Hospital Pulau Pinang
PRINCIPAL INVESTIGATOR
DR CHOONG SWEE HSIA
shchoong83@gmail.com
CONTACT
General line: 04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin, Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar, Admin Manager
zarinacu@gmail.com (Email)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
DR WONG YOKE FUI
florencefui@yahoo.com
CONTACT
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
Subtype: HR-Positive & HER2-negative
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)
Phase III, Line of treatment: 2nd &3rd Line , Failed endocrine therapy for chemotherapy candidate , PDL1-positive
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR MASTURA BINTI MD YUSOF
drmasturamy@gmail.com
03 – 2296 0764
CONTACT
General Line: 03 – 2296 0888
CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
DR NUR FADHLINA ABDUL SATAR
fadhlinas@ummc.edu.my
CONTACT
SC: Kimee Ku 03-79492120 (Research Room)
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
Dr Eznal Izwadi Mohd Mahidin
eznal.mahidin@gmail.com
CONTACT
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel) /
crc.hkl@moh.gov.my (email) /
Crc Hkl / Clinical Research Centre HKL (Facebook)
Hospital Pulau Pinang
PRINCIPAL INVESTIGATOR
Dr Tan Ai Lian
ailian.tan@gmail.com
CONTACT
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com, crcsghkuching@gmail.com (Email)
CLICK HERE (Facebook)
Subtype: HR-Negative & HER2-negative (Triple Negative)
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 (ASCENT-03)
Phase II, Line of treatment: 1st Line , PD-L1 poitive or PDL1 negtive treated with anti PD-L1 at early setting
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR MASTURA BINTI MD YUSOF
drmasturamy@gmail.com
03 – 2296 0764
CONTACT
SC: Nur Syifa
General Line: 03 – 2296 0888
CRC: 03 – 2781 0888 Ext 4519/4520/4522
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
WINNIE NG NYEK PING
CONTACT
SC: Abdul Hadi
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Dr Ngu Ming Ruey
CONTACT
SC: Tan Boon Sin
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
VAISHNAVI A/P JEYASINGAM
CONTACT
SC:Puteri Nur Najwa
Hospital Wanita dan Kanak-kanak Sabah
PRINCIPAL INVESTIGATOR
Dr Flora Chong Li Tze
CONTACT
SC: Roslin Guadih (016-8151234)
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
KUMUTHA A/P CHALAYA
CONTACT
SC: Farah Nadia Binti Mohd Hashim
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 (ASCENT-04)
Phase II, Line of treatment: 1st Line , PD-L1 poitive or PDL1 negtive treated with anti PD-L1 at early setting
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR MASTURA BINTI MD YUSOF
drmasturamy@gmail.com
03 – 2296 0764
CONTACT
General Line: 03 – 2296 0888
CRC: 03 – 2781 0888 Ext 4519/4520/4522
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
Dr Winnie Ng
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Dr Ngu Ming Ruey
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
Dr Kumutha Chalaya
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
DR ADLINDA ALIP
CONTACT
SC: Suga 03-79492120 (Research Room)
Hospital Wanita dan Kanak-kanak Sabah
PRINCIPAL INVESTIGATOR
Dr Flora Chong Li Tze
CONTACT
SC: Roslin Guadih (016-8151234)
Phase II Study to assess the efficacy of Talazoparib in asian mEtastatic breast caNcer patients with a hOmologous Recombinant deficiency (HRD) signature (TENOR)
Homologous recombinat Deficiency Metastatic Breast Cancer in Asian
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Ho Gwo Fuang
fuang@ummc.edu.my
CONTACT
SC: Wei Ying 03-79492120 (Research Room)
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR MASTURA BINTI MD YUSOF
drmasturamy@gmail.com
03 – 2296 0764
CONTACT
General Line: 03 – 2296 0888
CRC: 03 – 2781 0888 Ext 4519/4520/4522
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
DR LIM CHUN SEN
chunsen1@hotmail.com
CONTACT
General line: 07 – 356 5000
CRC: 07 – 356 5000 ext: 2408 /
Dr Munirah
Admin Manager
drmunirah@hsi.gov.my (Email)
Beacon Specialist Centre
PRINCIPAL INVESTIGATOR
Dr Kua Voon Fong
CONTACT
03-77872830
vfkua@beaconhospital.com.my (Email)
A Phase 3 Randomized, Open-Label Study Of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy(OPERA-01)
Phase III
Institut Kanser Negara
PRINCIPAL INVESTIGATOR
Norhidayu Binti Salimin
ayumin23@gmail.com
CONTACT
SC: Erda Syerena Rosli
erdasyerena@clinicalresearch.my
Hospital Pulau Pinang
PRINCIPAL INVESTIGATOR
Dr Choong Swee Hsia
shchoong83@gmail.com
CONTACT
SC: Nur Adilah Binti Abdul Aziz
nuradilah@clinicalresearch.my
Hospital Raja Permaisuri Bainun
PRINCIPAL INVESTIGATOR
Dr Angel Khor Nee Kwan
drangelkwan@gmail.com
CONTACT
SC: Revathe Rajendran
revathe@clinicalresearch.my
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy (TNBC) (ASCENT 07)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
Dr Heng Fook Yew
CONTACT
Ms. Lim Li Fang
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com, crcsghkuching@gmail.com (Email)
Facebook
Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
Dr Ibtisam Binti Mohd Nor
CONTACT
Ms. Faizah Mohd Hanapiah
General line: 04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin, Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar, Admin Manager
zarinacu@gmail.com (Email)
Institut Kanser Negara
PRINCIPAL INVESTIGATOR
Dr Suhana Binti Yusak
CONTACT
Ms. Anis Hazirah Binti Asmali Jauhari
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence (CAMBRIA-1)
Hospital Wanita dan Kanak-kanak Sabah
PRINCIPAL INVESTIGATOR
Dr Flora Chong Li Tze
CONTACT
SC: Nancy Nuau (016-375 2437)
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
LIM CHUN SEN
CONTACT
SC: Sri Ratha Balakrishnan